Please assess the completion status of the following clinical trial:

Trial Title: Drug-drug Interaction Study(CKD-501, Amlodipine)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 20 aged and 45 years old in healthy males~* Body weight ≥ 55kg and 18.5 ≤ IBW \< 25~* Agreement with written informed consent~Exclusion Criteria:~* Subject has a history affects the ADME of drug~* Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of party~* Inadequate subject by medical examination(medical history, physical examination, ECG, laboratory test)~* AST,ALT \> UNL \* 1.25 or Total bilirubin \> UNL \* 1.5~* Estimated GFR(MDRD) \< 80~* SBP \>150 mmHg, SBP \< 100 mmHg or DBP \> 100 mmHg, DBP \< 60 mmHg or Pulse \> 100 per/min, Pulse \< 50 per/min~* Substance abuse, or a history of drug abuse showed a positive for the party~* Continued to be taking caffeine (caffeine \> 5 cup/day), drinking (alcohol \> 210 g/week) or cannot stop drinking or severe heavy smoker(cigarette \> 10 cigarettes per day)during clinical trials~* Medication with drug-mediated induction/inhibition metabolic enzyme within 30 days or with may affect the clinical trial~* Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking~* Subject takes grapefruit within 1 month~* Previously participated in other trial within 60 days~* Previously donate whole blood within 60 days or component blood within 30 days~* An impossible one who participates in clinical trial by investigator's decision including laboratory test result

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CKD-501 0.5mg (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
- CKD-501 Amlodipine (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
- Amlodipine 10mg (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).